सैन डिएगो| लैंसेट पत्रिका में प्रकाशित एक अध्ययन में दावा किया गया है कि वयस्कों में क्रॉनिक किडनी रोग (सीकेडी) से पीड़ित कुछ लोगों के इलाज के लिए एक आम मधुमेह की दवा का इस्तेमाल किया जा सकता है। डैपाग्लीफ्लोजिन 'सोडियम ग्लूकोज कोट्रांसपोर्टर-2 (एसजीएलटी2) इनहिबिटर' नामक दवाओं के एक समूह से संबंध रखता है।
एसजीएलटी2 अवरोधक गुर्दे में एसजीएलटी2 प्रोटीन को अवरुद्ध करके काम करता है। इस प्रोटीन को अवरुद्ध करने से गुर्दे में दबाव और सूजन को कम करके गुर्दे की क्षति को कम किया जा सकता है। यह प्रोटीन को मूत्र में रिसने से रोकने में भी मदद करता है, और रक्तचाप और शरीर के वजन को कम करता है।
सीकेडी के साथ 4,304 प्रतिभागियों के नैदानिक परीक्षण से पता चला है कि डैपाग्लिफ्लोजि़न क्रॉनिक किडनी रोग (सीकेडी) के रोगियों में गुर्दे के कार्य में गिरावट की दर को कम करता है।
हालांकि मधुमेह के बिना प्रतिभागियों ने भी डैपाग्लिफ्लोजि़न के साथ गुर्दा समारोह में गिरावट की धीमी दर का अनुभव किया, क्योंकि मधुमेह वाले लोगों में डापाग्लिफ्लोजि़न का प्रभाव अधिक था।
यूनिवर्सिटी मेडिकल सेंटर ग्रोनिंगन के प्रमुख लेखक हिड्डो लैम्बर्स हीर्सपिंक ने कहा, "मुख्य निष्कर्ष यह है कि डैपाग्लिफ्लोजि़न सीकेडी के साथ और बिना टाइप 2 मधुमेह के रोगियों में प्रगतिशील किडनी फंक्शन लॉस को धीमा करने के लिए एक प्रभावी उपचार है।"
हीर्सपिंक ने कहा, "इसलिए, हार्टफेल या मृत्युदर के जोखिम को कम करने के अलावा, डैपाग्लिफ्लोजि़न भी गुर्दे के कार्य में गिरावट की प्रगति को धीमा कर देता है।"
शोध के निष्कर्ष 'एएसएन किडनी वीक 2021' के 4-7 नवंबर अंक में भी प्रस्तुत किए जाएंगे। (एजेंसी)
An Ayurvedic poly-herbal formulation, NEERI-KFT, has the potential to not only slow down the progression of chronic kidney disease but also restore normalcy in functional parameters of the vital organ, a team of researchers has claimed.
In a review published in the latest edition of Saudi Journal of Biological Sciences, they said "phytopharmacological evaluation of NEERI-KFT suggests that it exhibits substantial potential against oxidative and inflammatory stress induced apoptosis by exerting antioxidant, nephroprotective and immunomodulatory effects...in the patients associated with renal dysfunction or chronic kidney disease (CKD)".
The NEERI-KFT, a herbal medicine extracted from plants, has been found to correct oxidative as well as inflammatory stress known for reducing body's immunity, said the authors after drawing data on the formulation for kidney ailments from more than five electronic databases such as Science Direct, Google Scholar, Elsevier, PubMed, Springer, ACS publication from published database between 2000 and 2020.
Buy Online► Aimil Neeri KFT Syrup
The study, 'A systematic review on nephroprotective AYUSH drugs as constituents of NEERI-KFT' not only examined the impact of the herbal extract of NEERI-KFT prepared by the AIMIL Pharma interventions on patients, but also dwelled in detail the adverse events of the modern medicine used for the management of the kidney ailments.
The study also highlighted the herbal drug's efficacy in reducing "serum creatinine, blood urea, and serum uric acid as compared to placebo group" and described "its well-tolerated effect with no adverse hematological or biochemical abnormalities occurred to any subjects during clinical trial".
"It can be suggested that NEERI-KFT can be an alternative and complementary therapy at end-stage renal disease (ESRD) or complete loss of kidney function where frequent dialysis of renal transplant remains only a single option for continued survival CKD patients," researchers said.
K.K. Sharma, AIMIL Pharma Managing Director, attributed this to the "more than 20 different potent herbs like haridra, varuna, shirish, gokhru, punarnava and anantamul to name a few in the formulation which are known for their nephro corrective, anti-inflammatory and antioxidant properties and reparative regeneration of kidney cells.
Also, Read This► किडनी के लिए संजीवनी बनी आयुर्वेदिक दवा नीरी केएफटी : अध्ययन
It was after a string of stringent tests that this formulation has been developed to provide relief to kidney patients, he said.
K.N. Dwivedi from Banaras Hindu University said the herbal ingredients in NEERI-KFT are loaded with many anti-oxidants besides medicinal values which not only strengthen kidney but liver also.
"This is a very unique drug and we have found it very effective in our study also," he added.
Read More► Aimil Neeri KFT Syrup: Benefits, Side Effects, Composition and Dosage
Bengaluru, Aug 17 (IANS) In view of a possible third wave of the Covid-19 pandemic, Karnataka will launch a drive to check the spread of Tuberculosis (TB) that might hit Covid patients post recovery, an official said here on Monday.According to a statement released by the health department, doctors have been witnessing a rise in the number of TB cases and that too predominantly among Covid patients post recovery."We are launching a door-to-door survey to detect the four common symptoms of TB. Our team of healthcare and ASHA workers will carry out an active case survey by visiting each house with Covid patients," said the statement.According to the note, even the Union Health Ministry had in 2020 recommended TB screening for all Covid patients."The survey will be conducted from the PHC level and the houses of all Covid-recovered patients will be visited, and their family members, primary and secondary contacts will be identified and screened for TB," the statement said.TB is an endemic in India and during prolonged intermittent lockdowns since March last year, many people could not consult doctors despite developing symptoms.In many cases, people also confused the symptoms of TB with Covid as both the communicable diseases are infectious in nature, which primarily attack the lungs.They present similar symptoms of cough, fever and difficulty in breathing, although TB has a longer incubation period and a slower onset time. The prevalence of TB among Covid patients has been found to be 0.37-4.47 per cent in different studies.Covid could make an individual more susceptible to developing TB, as the latter is an opportunistic infection like the black fungus.According to the National Strategic Plan for TB Elimination, a government programme that aims to eliminate the disease in India by 2025, TB kills an estimated 4.8 lakh Indians every year or more than 1,400 every day.--IANSnbh/arm
Washington, Aug 11 (IANS) The US National Institutes of Health (NIH) has launched a pilot study to assess the antibody response to a third dose of a Covid-19 mRNA vaccine in kidney transplant recipients who did not respond to a two-dose shot of Moderna or Pfizer-BioNTech.The pilot study, called Covid Protection After Transplant (CPAT), will be conducted at Johns Hopkins University in Baltimore, US. The team will enrol up to 200 adults aged 18 years or older who received a kidney transplant a year or more prior to enrolment and have had no recent organ rejection or change in immunosuppression, the NIH said in a statement. The lifelong immunosuppressive therapy that organ transplant recipients must take to prevent organ rejection blunts their immune response to both pathogens and vaccines. Research has shown that many organ transplant recipients do not develop antibodies against SARS-CoV-2, the virus that causes Covid-19, after receiving Covid-19 vaccines. The study aims to determine whether a third dose of one of the mRNA Covid-19 vaccines could overcome this problem for at least some kidney transplant recipients. This is particularly important because this population has a high prevalence of conditions that are risk factors for severe Covid-19, such as cardiovascular disease and diabetes.The pilot study also aims to identify characteristics that could help distinguish those kidney transplant recipients who would benefit from a third dose of an mRNA vaccine from those who will require a different approach to achieve protection. The third-dose vaccine intervention was chosen because of the demonstrated safety of the two-dose mRNA vaccine regimen in solid organ transplant recipients as well as the efficacy of additional doses of other vaccines, such as those for hepatitis and influenza, in immunocompromised people, the NIH said.The study participants will be followed for one year after enrolment. Preliminary results are expected in September 2021.--IANSrvt/bg
Noida, Aug 5 (IANS) A 80-year-old mother has donated her kidney to save the life of her son, displaying the epitome of love and sacrifice. The case has entered the India Book of Records for the 'aged living female kidney donor'.Madeleine, a farmer from Cameroon (Gulf of Guinea, Central Africa), donated a kidney to her son Joseph, 52, who was suffering from a prolonged kidney disease resulting in kidney failure. A team of doctors at Jaypee Hospital successfully conducted the highly complicated kidney transplant surgery, the hospital said in a statement on Thursday."Madeleine's old age was of a major concern for us as mostly the health of the kidney starts deteriorating after the age of 65. After proper evaluation, it was found that she had good kidney functions and was found medically fit to donate her kidney," said Amit K Devra, Director, Coordinator Kidney Transplant Programme, Department of Urology and Kidney Transplant at Jaypee, which has successfully completed more than 650 kidney transplants. "However, she had a complex kidney anatomy with two renal arteries and two ureters for which we had to connect two tubes instead of one for the proper renal functioning," said Amit K Devra, Director, Coordinator Kidney Transplant Programme, Department of Urology and Kidney Transplant at Jaypee, in a statement. "Generally, normal people have one renal artery and ureters. A small stone was also diagnosed in her kidney. This made the process even more complicated, but without any hesitation, we took up the challenge in order to save our patient's life," he added. Madeleine's kidney harvesting was done laparoscopically to reduce the post-operative pain. After kidney removal, the stone was removed (ex vivo) while the kidney was in an ice bucket for perfusion. Both renal arteries were then connected separately with the recipient's blood vessels, the doctor said."It takes an incredible amount of strength, endurance and faith to donate a kidney at this age. She did not lose hope and her strong will to save her son's life pushed her to not give up at any point. The donor was discharged on the fifth post-operative day, whereas the recipient was discharged on the eighth post-operative day," said Dr Vijay K Sinha, Associate Director, Department of Nephrology and Kidney Transplant at the hospital.The team of doctors who successfully conducted the complicated kidney transplant surgery had Dr Devra, Dr Sinha, Dr LP Chowdhury, Dr Ravi Singh, Dr Anuj Arora, Dr Khushboo Singh and other paramedical staff.--IANSrvt/na
New Delhi, July 31 (IANS) The Ayush ministry's All India Institute of Ayurveda in collaboration with the United Kingdom's London School of Hygiene and Tropical Medicine will conduct a study on 'Ashwagandha' for promoting recovery from Covid-19 in a boost to the traditional Indian medicine system.Both the institutions signed a Memorandum of Understanding to conduct the clinical trials of Ashwagandha on 2,000 people in three UK cities -- Leicester, Birmingham, and London (Southall and Wembley), said the ministry in a statement.Ashwagandha (Withania Somnifera), commonly known as 'Indian winter cherry', is a traditional Indian herb that boosts energy, reduces stress, and makes the immune system stronger.It is an easily accessible, over-the-counter nutritional supplement in the UK and has a proven safety profile. The positive effects of Ashwagandha have been observed in Covid, which is a multi-system disease with no evidence of its effective treatment or management.The successful completion of the trial can be a major breakthrough and give scientific validity to India's traditional medicinal system. While there have been several studies on Ashwagandha to understand its benefits in various ailments, this is the first time the Ministry has collaborated with a foreign institution to investigate its efficacy on Covid-19 patients.AIIA director Dr Tanuja Manoj Nesari, who is also a co-investigator in the project along with Dr Rajgopalan, Coordinator - International Projects, said that the participants have been randomly selected. Dr Sanjay Kinra of LSHTM is the principal investigator of the study.The participants will have to take the 500mg tablets twice a day. A monthly follow-up of self-reported quality of life, impairment to activities of daily living, mental and physical health symptoms, supplement use and adverse events will be carried out."For three months, one group of 1,000 participants will be administered Ashwagandha (AG) tablets while the second group of 1,000 participants will be assigned a placebo, which is indistinguishable from AG in looks and taste. Both patients and the doctors will be unaware of the group's treatment in a double-blind trial," Dr Nesari said.--IANSstr/sk/bg